Review



mouse primary embryonic fibroblasts  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    ATCC mouse primary embryonic fibroblasts
    Mouse Primary Embryonic Fibroblasts, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 33 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse primary embryonic fibroblasts/product/ATCC
    Average 94 stars, based on 33 article reviews
    mouse primary embryonic fibroblasts - by Bioz Stars, 2026-05
    94/100 stars

    Images



    Similar Products

    94
    ATCC mouse primary embryonic fibroblasts
    Mouse Primary Embryonic Fibroblasts, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse primary embryonic fibroblasts/product/ATCC
    Average 94 stars, based on 1 article reviews
    mouse primary embryonic fibroblasts - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    99
    ATCC crl 1573 primary mouse embryonic fibroblast
    Crl 1573 Primary Mouse Embryonic Fibroblast, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/crl 1573 primary mouse embryonic fibroblast/product/ATCC
    Average 99 stars, based on 1 article reviews
    crl 1573 primary mouse embryonic fibroblast - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    86
    China Pharmaceuticals Inc primary mouse embryonic fibroblasts mefs
    Primary Mouse Embryonic Fibroblasts Mefs, supplied by China Pharmaceuticals Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary mouse embryonic fibroblasts mefs/product/China Pharmaceuticals Inc
    Average 86 stars, based on 1 article reviews
    primary mouse embryonic fibroblasts mefs - by Bioz Stars, 2026-05
    86/100 stars
      Buy from Supplier

    86
    Orient Bio Company primary mouse embryonic fibroblasts mefs
    (a) Illustration of C12-SPM-GAL LNP-mRNA formulation. Chemical structure of the ionizable lipid C12-SPM and the lipid components with their respective molar ratios in the optimized C12-SPM-GAL LNP-mRNA formulation. (b) Biochemical assays for serum ALT and AST levels (n = 3) 24 h after intravenous (IV) administration of LNPs loaded with firefly luciferase mRNA (0.3 mg/kg) in C57BL/6 mice. PBS; PBS-injected mice, MC3; DLin-MC3-DMA LNP-injected mice, GAL; C12-SPM-GAL LNP-injected mice. (c) Time-course analysis of in vivo bioluminescence following IV administration of LNPs loaded with firefly luciferase mRNA in C57BL/6 mice (0.3 mg/kg) (n = 3 ∼ 4). (d) Detection of OSKM proteins 24 h after transfection of C12-SPM-GAL LNPs loaded with OSKM mRNA into <t>MEFs</t> (1 μg total OSKM mRNA for 100,000 cells, 0.25 μg for each mRNA). NT; no treatment, OSKM; OSKM mRNA-LNP treatment. (e) Experimental outline for assessing in vivo partial reprogramming by OSKM mRNA-LNP to induce hepatocyte dedifferentiation in normal wild-type mice. The PBS-injected group (PBS group) was used as a negative control, and both Luc mRNA-LNP (Luc group) and OSKM mRNA-LNP (OSKM group) were IV administered at a dose of 0.3 mg/kg. (f) Quantitative PCR analysis of liver progenitor-like cell (LPLC)-related genes in the liver 30 h post-injection (n = 4 ∼ 5). (g) Immunofluorescence staining of Sox9 and Ki-67 co-stained with Hnf4α in the liver 30 h post-injection. DAPI stains the nuclei (scale bars = 100 μm). (h) Western blot analysis for LPLC marker Sox9, cell cycle marker phosphorylated histone H3 (pHH3), and proliferating cell nuclear antigen (PCNA) in the liver 30 and 54 h post-injection. (i) Schematic illustration of C12-SPM-GAL-mediated OSKM mRNA treatment in an acetaminophen (APAP)-induced acute liver injury mouse model. C57BL/6 mice received intraperitoneal injection of APAP at a dose of 400 mg/kg after fasting for 12 h. Mice were treated with PBS (Mock group), Luc mRNA-LNP (Luc group), or OSKM mRNA-LNP (OSKM group) 18 h post-APAP administration. (j) Kaplan-Meier survival plot of mice (n = 14) in each treatment group over four days following APAP administration. Cont; normal mice, Mock; APAP injury + PBS-injected mice, Luc; APAP injury + Luc mRNA-LNP-injected mice, OSKM; APAP injury + OSKM mRNA-LNP-injected mice. (k) Blood chemistry analysis of serum AST and ALT levels 96 hours post-APAP administration (78 hours post-treatment). (l) Representative images of the whole livers and H&E staining 96 hours post-APAP administration (78 hours post-treatment) (left panel) (scale bars = 500 μm). Dotted lines indicate necrotic areas. Quantification of the necrotic area in three H&E-stained sections per mouse liver sample (right panel) (n = 4 mice per group). (m) Immunostaining for cleaved caspase-3 (cCasp3) (red) in the pericentral region of the liver, with nuclei counterstained with DAPI (blue) (scale bar = 100 μm). CV indicates the central vein. (n) Western blot analysis for cleaved caspase-3 (cCasp3) 96 h post-APAP administration (78 h post-LNP injection at indicated mRNA doses). Vinculin was used as an internal control. Statistical analysis was performed using one-way ANOVA: p < 0.01(**), p < 0.001(***), ns, not significant.
    Primary Mouse Embryonic Fibroblasts Mefs, supplied by Orient Bio Company, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary mouse embryonic fibroblasts mefs/product/Orient Bio Company
    Average 86 stars, based on 1 article reviews
    primary mouse embryonic fibroblasts mefs - by Bioz Stars, 2026-05
    86/100 stars
      Buy from Supplier

    90
    Lonza primary mouse embryonic fibroblasts (pmef)
    (a) Illustration of C12-SPM-GAL LNP-mRNA formulation. Chemical structure of the ionizable lipid C12-SPM and the lipid components with their respective molar ratios in the optimized C12-SPM-GAL LNP-mRNA formulation. (b) Biochemical assays for serum ALT and AST levels (n = 3) 24 h after intravenous (IV) administration of LNPs loaded with firefly luciferase mRNA (0.3 mg/kg) in C57BL/6 mice. PBS; PBS-injected mice, MC3; DLin-MC3-DMA LNP-injected mice, GAL; C12-SPM-GAL LNP-injected mice. (c) Time-course analysis of in vivo bioluminescence following IV administration of LNPs loaded with firefly luciferase mRNA in C57BL/6 mice (0.3 mg/kg) (n = 3 ∼ 4). (d) Detection of OSKM proteins 24 h after transfection of C12-SPM-GAL LNPs loaded with OSKM mRNA into <t>MEFs</t> (1 μg total OSKM mRNA for 100,000 cells, 0.25 μg for each mRNA). NT; no treatment, OSKM; OSKM mRNA-LNP treatment. (e) Experimental outline for assessing in vivo partial reprogramming by OSKM mRNA-LNP to induce hepatocyte dedifferentiation in normal wild-type mice. The PBS-injected group (PBS group) was used as a negative control, and both Luc mRNA-LNP (Luc group) and OSKM mRNA-LNP (OSKM group) were IV administered at a dose of 0.3 mg/kg. (f) Quantitative PCR analysis of liver progenitor-like cell (LPLC)-related genes in the liver 30 h post-injection (n = 4 ∼ 5). (g) Immunofluorescence staining of Sox9 and Ki-67 co-stained with Hnf4α in the liver 30 h post-injection. DAPI stains the nuclei (scale bars = 100 μm). (h) Western blot analysis for LPLC marker Sox9, cell cycle marker phosphorylated histone H3 (pHH3), and proliferating cell nuclear antigen (PCNA) in the liver 30 and 54 h post-injection. (i) Schematic illustration of C12-SPM-GAL-mediated OSKM mRNA treatment in an acetaminophen (APAP)-induced acute liver injury mouse model. C57BL/6 mice received intraperitoneal injection of APAP at a dose of 400 mg/kg after fasting for 12 h. Mice were treated with PBS (Mock group), Luc mRNA-LNP (Luc group), or OSKM mRNA-LNP (OSKM group) 18 h post-APAP administration. (j) Kaplan-Meier survival plot of mice (n = 14) in each treatment group over four days following APAP administration. Cont; normal mice, Mock; APAP injury + PBS-injected mice, Luc; APAP injury + Luc mRNA-LNP-injected mice, OSKM; APAP injury + OSKM mRNA-LNP-injected mice. (k) Blood chemistry analysis of serum AST and ALT levels 96 hours post-APAP administration (78 hours post-treatment). (l) Representative images of the whole livers and H&E staining 96 hours post-APAP administration (78 hours post-treatment) (left panel) (scale bars = 500 μm). Dotted lines indicate necrotic areas. Quantification of the necrotic area in three H&E-stained sections per mouse liver sample (right panel) (n = 4 mice per group). (m) Immunostaining for cleaved caspase-3 (cCasp3) (red) in the pericentral region of the liver, with nuclei counterstained with DAPI (blue) (scale bar = 100 μm). CV indicates the central vein. (n) Western blot analysis for cleaved caspase-3 (cCasp3) 96 h post-APAP administration (78 h post-LNP injection at indicated mRNA doses). Vinculin was used as an internal control. Statistical analysis was performed using one-way ANOVA: p < 0.01(**), p < 0.001(***), ns, not significant.
    Primary Mouse Embryonic Fibroblasts (Pmef), supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary mouse embryonic fibroblasts (pmef)/product/Lonza
    Average 90 stars, based on 1 article reviews
    primary mouse embryonic fibroblasts (pmef) - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    Lonza primary mouse embryonic fibroblasts
    (a) Illustration of C12-SPM-GAL LNP-mRNA formulation. Chemical structure of the ionizable lipid C12-SPM and the lipid components with their respective molar ratios in the optimized C12-SPM-GAL LNP-mRNA formulation. (b) Biochemical assays for serum ALT and AST levels (n = 3) 24 h after intravenous (IV) administration of LNPs loaded with firefly luciferase mRNA (0.3 mg/kg) in C57BL/6 mice. PBS; PBS-injected mice, MC3; DLin-MC3-DMA LNP-injected mice, GAL; C12-SPM-GAL LNP-injected mice. (c) Time-course analysis of in vivo bioluminescence following IV administration of LNPs loaded with firefly luciferase mRNA in C57BL/6 mice (0.3 mg/kg) (n = 3 ∼ 4). (d) Detection of OSKM proteins 24 h after transfection of C12-SPM-GAL LNPs loaded with OSKM mRNA into <t>MEFs</t> (1 μg total OSKM mRNA for 100,000 cells, 0.25 μg for each mRNA). NT; no treatment, OSKM; OSKM mRNA-LNP treatment. (e) Experimental outline for assessing in vivo partial reprogramming by OSKM mRNA-LNP to induce hepatocyte dedifferentiation in normal wild-type mice. The PBS-injected group (PBS group) was used as a negative control, and both Luc mRNA-LNP (Luc group) and OSKM mRNA-LNP (OSKM group) were IV administered at a dose of 0.3 mg/kg. (f) Quantitative PCR analysis of liver progenitor-like cell (LPLC)-related genes in the liver 30 h post-injection (n = 4 ∼ 5). (g) Immunofluorescence staining of Sox9 and Ki-67 co-stained with Hnf4α in the liver 30 h post-injection. DAPI stains the nuclei (scale bars = 100 μm). (h) Western blot analysis for LPLC marker Sox9, cell cycle marker phosphorylated histone H3 (pHH3), and proliferating cell nuclear antigen (PCNA) in the liver 30 and 54 h post-injection. (i) Schematic illustration of C12-SPM-GAL-mediated OSKM mRNA treatment in an acetaminophen (APAP)-induced acute liver injury mouse model. C57BL/6 mice received intraperitoneal injection of APAP at a dose of 400 mg/kg after fasting for 12 h. Mice were treated with PBS (Mock group), Luc mRNA-LNP (Luc group), or OSKM mRNA-LNP (OSKM group) 18 h post-APAP administration. (j) Kaplan-Meier survival plot of mice (n = 14) in each treatment group over four days following APAP administration. Cont; normal mice, Mock; APAP injury + PBS-injected mice, Luc; APAP injury + Luc mRNA-LNP-injected mice, OSKM; APAP injury + OSKM mRNA-LNP-injected mice. (k) Blood chemistry analysis of serum AST and ALT levels 96 hours post-APAP administration (78 hours post-treatment). (l) Representative images of the whole livers and H&E staining 96 hours post-APAP administration (78 hours post-treatment) (left panel) (scale bars = 500 μm). Dotted lines indicate necrotic areas. Quantification of the necrotic area in three H&E-stained sections per mouse liver sample (right panel) (n = 4 mice per group). (m) Immunostaining for cleaved caspase-3 (cCasp3) (red) in the pericentral region of the liver, with nuclei counterstained with DAPI (blue) (scale bar = 100 μm). CV indicates the central vein. (n) Western blot analysis for cleaved caspase-3 (cCasp3) 96 h post-APAP administration (78 h post-LNP injection at indicated mRNA doses). Vinculin was used as an internal control. Statistical analysis was performed using one-way ANOVA: p < 0.01(**), p < 0.001(***), ns, not significant.
    Primary Mouse Embryonic Fibroblasts, supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary mouse embryonic fibroblasts/product/Lonza
    Average 90 stars, based on 1 article reviews
    primary mouse embryonic fibroblasts - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    Orient Bio Company primary mouse embryonic fibroblasts (pmefs)
    (a) Illustration of C12-SPM-GAL LNP-mRNA formulation. Chemical structure of the ionizable lipid C12-SPM and the lipid components with their respective molar ratios in the optimized C12-SPM-GAL LNP-mRNA formulation. (b) Biochemical assays for serum ALT and AST levels (n = 3) 24 h after intravenous (IV) administration of LNPs loaded with firefly luciferase mRNA (0.3 mg/kg) in C57BL/6 mice. PBS; PBS-injected mice, MC3; DLin-MC3-DMA LNP-injected mice, GAL; C12-SPM-GAL LNP-injected mice. (c) Time-course analysis of in vivo bioluminescence following IV administration of LNPs loaded with firefly luciferase mRNA in C57BL/6 mice (0.3 mg/kg) (n = 3 ∼ 4). (d) Detection of OSKM proteins 24 h after transfection of C12-SPM-GAL LNPs loaded with OSKM mRNA into <t>MEFs</t> (1 μg total OSKM mRNA for 100,000 cells, 0.25 μg for each mRNA). NT; no treatment, OSKM; OSKM mRNA-LNP treatment. (e) Experimental outline for assessing in vivo partial reprogramming by OSKM mRNA-LNP to induce hepatocyte dedifferentiation in normal wild-type mice. The PBS-injected group (PBS group) was used as a negative control, and both Luc mRNA-LNP (Luc group) and OSKM mRNA-LNP (OSKM group) were IV administered at a dose of 0.3 mg/kg. (f) Quantitative PCR analysis of liver progenitor-like cell (LPLC)-related genes in the liver 30 h post-injection (n = 4 ∼ 5). (g) Immunofluorescence staining of Sox9 and Ki-67 co-stained with Hnf4α in the liver 30 h post-injection. DAPI stains the nuclei (scale bars = 100 μm). (h) Western blot analysis for LPLC marker Sox9, cell cycle marker phosphorylated histone H3 (pHH3), and proliferating cell nuclear antigen (PCNA) in the liver 30 and 54 h post-injection. (i) Schematic illustration of C12-SPM-GAL-mediated OSKM mRNA treatment in an acetaminophen (APAP)-induced acute liver injury mouse model. C57BL/6 mice received intraperitoneal injection of APAP at a dose of 400 mg/kg after fasting for 12 h. Mice were treated with PBS (Mock group), Luc mRNA-LNP (Luc group), or OSKM mRNA-LNP (OSKM group) 18 h post-APAP administration. (j) Kaplan-Meier survival plot of mice (n = 14) in each treatment group over four days following APAP administration. Cont; normal mice, Mock; APAP injury + PBS-injected mice, Luc; APAP injury + Luc mRNA-LNP-injected mice, OSKM; APAP injury + OSKM mRNA-LNP-injected mice. (k) Blood chemistry analysis of serum AST and ALT levels 96 hours post-APAP administration (78 hours post-treatment). (l) Representative images of the whole livers and H&E staining 96 hours post-APAP administration (78 hours post-treatment) (left panel) (scale bars = 500 μm). Dotted lines indicate necrotic areas. Quantification of the necrotic area in three H&E-stained sections per mouse liver sample (right panel) (n = 4 mice per group). (m) Immunostaining for cleaved caspase-3 (cCasp3) (red) in the pericentral region of the liver, with nuclei counterstained with DAPI (blue) (scale bar = 100 μm). CV indicates the central vein. (n) Western blot analysis for cleaved caspase-3 (cCasp3) 96 h post-APAP administration (78 h post-LNP injection at indicated mRNA doses). Vinculin was used as an internal control. Statistical analysis was performed using one-way ANOVA: p < 0.01(**), p < 0.001(***), ns, not significant.
    Primary Mouse Embryonic Fibroblasts (Pmefs), supplied by Orient Bio Company, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary mouse embryonic fibroblasts (pmefs)/product/Orient Bio Company
    Average 90 stars, based on 1 article reviews
    primary mouse embryonic fibroblasts (pmefs) - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    90
    Nature Biotechnology primary mouse embryonic fibroblasts (mefs)
    (a) Illustration of C12-SPM-GAL LNP-mRNA formulation. Chemical structure of the ionizable lipid C12-SPM and the lipid components with their respective molar ratios in the optimized C12-SPM-GAL LNP-mRNA formulation. (b) Biochemical assays for serum ALT and AST levels (n = 3) 24 h after intravenous (IV) administration of LNPs loaded with firefly luciferase mRNA (0.3 mg/kg) in C57BL/6 mice. PBS; PBS-injected mice, MC3; DLin-MC3-DMA LNP-injected mice, GAL; C12-SPM-GAL LNP-injected mice. (c) Time-course analysis of in vivo bioluminescence following IV administration of LNPs loaded with firefly luciferase mRNA in C57BL/6 mice (0.3 mg/kg) (n = 3 ∼ 4). (d) Detection of OSKM proteins 24 h after transfection of C12-SPM-GAL LNPs loaded with OSKM mRNA into <t>MEFs</t> (1 μg total OSKM mRNA for 100,000 cells, 0.25 μg for each mRNA). NT; no treatment, OSKM; OSKM mRNA-LNP treatment. (e) Experimental outline for assessing in vivo partial reprogramming by OSKM mRNA-LNP to induce hepatocyte dedifferentiation in normal wild-type mice. The PBS-injected group (PBS group) was used as a negative control, and both Luc mRNA-LNP (Luc group) and OSKM mRNA-LNP (OSKM group) were IV administered at a dose of 0.3 mg/kg. (f) Quantitative PCR analysis of liver progenitor-like cell (LPLC)-related genes in the liver 30 h post-injection (n = 4 ∼ 5). (g) Immunofluorescence staining of Sox9 and Ki-67 co-stained with Hnf4α in the liver 30 h post-injection. DAPI stains the nuclei (scale bars = 100 μm). (h) Western blot analysis for LPLC marker Sox9, cell cycle marker phosphorylated histone H3 (pHH3), and proliferating cell nuclear antigen (PCNA) in the liver 30 and 54 h post-injection. (i) Schematic illustration of C12-SPM-GAL-mediated OSKM mRNA treatment in an acetaminophen (APAP)-induced acute liver injury mouse model. C57BL/6 mice received intraperitoneal injection of APAP at a dose of 400 mg/kg after fasting for 12 h. Mice were treated with PBS (Mock group), Luc mRNA-LNP (Luc group), or OSKM mRNA-LNP (OSKM group) 18 h post-APAP administration. (j) Kaplan-Meier survival plot of mice (n = 14) in each treatment group over four days following APAP administration. Cont; normal mice, Mock; APAP injury + PBS-injected mice, Luc; APAP injury + Luc mRNA-LNP-injected mice, OSKM; APAP injury + OSKM mRNA-LNP-injected mice. (k) Blood chemistry analysis of serum AST and ALT levels 96 hours post-APAP administration (78 hours post-treatment). (l) Representative images of the whole livers and H&E staining 96 hours post-APAP administration (78 hours post-treatment) (left panel) (scale bars = 500 μm). Dotted lines indicate necrotic areas. Quantification of the necrotic area in three H&E-stained sections per mouse liver sample (right panel) (n = 4 mice per group). (m) Immunostaining for cleaved caspase-3 (cCasp3) (red) in the pericentral region of the liver, with nuclei counterstained with DAPI (blue) (scale bar = 100 μm). CV indicates the central vein. (n) Western blot analysis for cleaved caspase-3 (cCasp3) 96 h post-APAP administration (78 h post-LNP injection at indicated mRNA doses). Vinculin was used as an internal control. Statistical analysis was performed using one-way ANOVA: p < 0.01(**), p < 0.001(***), ns, not significant.
    Primary Mouse Embryonic Fibroblasts (Mefs), supplied by Nature Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary mouse embryonic fibroblasts (mefs)/product/Nature Biotechnology
    Average 90 stars, based on 1 article reviews
    primary mouse embryonic fibroblasts (mefs) - by Bioz Stars, 2026-05
    90/100 stars
      Buy from Supplier

    94
    ATCC primary mouse embryonic fibroblast mef wt
    (a) Illustration of C12-SPM-GAL LNP-mRNA formulation. Chemical structure of the ionizable lipid C12-SPM and the lipid components with their respective molar ratios in the optimized C12-SPM-GAL LNP-mRNA formulation. (b) Biochemical assays for serum ALT and AST levels (n = 3) 24 h after intravenous (IV) administration of LNPs loaded with firefly luciferase mRNA (0.3 mg/kg) in C57BL/6 mice. PBS; PBS-injected mice, MC3; DLin-MC3-DMA LNP-injected mice, GAL; C12-SPM-GAL LNP-injected mice. (c) Time-course analysis of in vivo bioluminescence following IV administration of LNPs loaded with firefly luciferase mRNA in C57BL/6 mice (0.3 mg/kg) (n = 3 ∼ 4). (d) Detection of OSKM proteins 24 h after transfection of C12-SPM-GAL LNPs loaded with OSKM mRNA into <t>MEFs</t> (1 μg total OSKM mRNA for 100,000 cells, 0.25 μg for each mRNA). NT; no treatment, OSKM; OSKM mRNA-LNP treatment. (e) Experimental outline for assessing in vivo partial reprogramming by OSKM mRNA-LNP to induce hepatocyte dedifferentiation in normal wild-type mice. The PBS-injected group (PBS group) was used as a negative control, and both Luc mRNA-LNP (Luc group) and OSKM mRNA-LNP (OSKM group) were IV administered at a dose of 0.3 mg/kg. (f) Quantitative PCR analysis of liver progenitor-like cell (LPLC)-related genes in the liver 30 h post-injection (n = 4 ∼ 5). (g) Immunofluorescence staining of Sox9 and Ki-67 co-stained with Hnf4α in the liver 30 h post-injection. DAPI stains the nuclei (scale bars = 100 μm). (h) Western blot analysis for LPLC marker Sox9, cell cycle marker phosphorylated histone H3 (pHH3), and proliferating cell nuclear antigen (PCNA) in the liver 30 and 54 h post-injection. (i) Schematic illustration of C12-SPM-GAL-mediated OSKM mRNA treatment in an acetaminophen (APAP)-induced acute liver injury mouse model. C57BL/6 mice received intraperitoneal injection of APAP at a dose of 400 mg/kg after fasting for 12 h. Mice were treated with PBS (Mock group), Luc mRNA-LNP (Luc group), or OSKM mRNA-LNP (OSKM group) 18 h post-APAP administration. (j) Kaplan-Meier survival plot of mice (n = 14) in each treatment group over four days following APAP administration. Cont; normal mice, Mock; APAP injury + PBS-injected mice, Luc; APAP injury + Luc mRNA-LNP-injected mice, OSKM; APAP injury + OSKM mRNA-LNP-injected mice. (k) Blood chemistry analysis of serum AST and ALT levels 96 hours post-APAP administration (78 hours post-treatment). (l) Representative images of the whole livers and H&E staining 96 hours post-APAP administration (78 hours post-treatment) (left panel) (scale bars = 500 μm). Dotted lines indicate necrotic areas. Quantification of the necrotic area in three H&E-stained sections per mouse liver sample (right panel) (n = 4 mice per group). (m) Immunostaining for cleaved caspase-3 (cCasp3) (red) in the pericentral region of the liver, with nuclei counterstained with DAPI (blue) (scale bar = 100 μm). CV indicates the central vein. (n) Western blot analysis for cleaved caspase-3 (cCasp3) 96 h post-APAP administration (78 h post-LNP injection at indicated mRNA doses). Vinculin was used as an internal control. Statistical analysis was performed using one-way ANOVA: p < 0.01(**), p < 0.001(***), ns, not significant.
    Primary Mouse Embryonic Fibroblast Mef Wt, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary mouse embryonic fibroblast mef wt/product/ATCC
    Average 94 stars, based on 1 article reviews
    primary mouse embryonic fibroblast mef wt - by Bioz Stars, 2026-05
    94/100 stars
      Buy from Supplier

    Image Search Results


    (a) Illustration of C12-SPM-GAL LNP-mRNA formulation. Chemical structure of the ionizable lipid C12-SPM and the lipid components with their respective molar ratios in the optimized C12-SPM-GAL LNP-mRNA formulation. (b) Biochemical assays for serum ALT and AST levels (n = 3) 24 h after intravenous (IV) administration of LNPs loaded with firefly luciferase mRNA (0.3 mg/kg) in C57BL/6 mice. PBS; PBS-injected mice, MC3; DLin-MC3-DMA LNP-injected mice, GAL; C12-SPM-GAL LNP-injected mice. (c) Time-course analysis of in vivo bioluminescence following IV administration of LNPs loaded with firefly luciferase mRNA in C57BL/6 mice (0.3 mg/kg) (n = 3 ∼ 4). (d) Detection of OSKM proteins 24 h after transfection of C12-SPM-GAL LNPs loaded with OSKM mRNA into MEFs (1 μg total OSKM mRNA for 100,000 cells, 0.25 μg for each mRNA). NT; no treatment, OSKM; OSKM mRNA-LNP treatment. (e) Experimental outline for assessing in vivo partial reprogramming by OSKM mRNA-LNP to induce hepatocyte dedifferentiation in normal wild-type mice. The PBS-injected group (PBS group) was used as a negative control, and both Luc mRNA-LNP (Luc group) and OSKM mRNA-LNP (OSKM group) were IV administered at a dose of 0.3 mg/kg. (f) Quantitative PCR analysis of liver progenitor-like cell (LPLC)-related genes in the liver 30 h post-injection (n = 4 ∼ 5). (g) Immunofluorescence staining of Sox9 and Ki-67 co-stained with Hnf4α in the liver 30 h post-injection. DAPI stains the nuclei (scale bars = 100 μm). (h) Western blot analysis for LPLC marker Sox9, cell cycle marker phosphorylated histone H3 (pHH3), and proliferating cell nuclear antigen (PCNA) in the liver 30 and 54 h post-injection. (i) Schematic illustration of C12-SPM-GAL-mediated OSKM mRNA treatment in an acetaminophen (APAP)-induced acute liver injury mouse model. C57BL/6 mice received intraperitoneal injection of APAP at a dose of 400 mg/kg after fasting for 12 h. Mice were treated with PBS (Mock group), Luc mRNA-LNP (Luc group), or OSKM mRNA-LNP (OSKM group) 18 h post-APAP administration. (j) Kaplan-Meier survival plot of mice (n = 14) in each treatment group over four days following APAP administration. Cont; normal mice, Mock; APAP injury + PBS-injected mice, Luc; APAP injury + Luc mRNA-LNP-injected mice, OSKM; APAP injury + OSKM mRNA-LNP-injected mice. (k) Blood chemistry analysis of serum AST and ALT levels 96 hours post-APAP administration (78 hours post-treatment). (l) Representative images of the whole livers and H&E staining 96 hours post-APAP administration (78 hours post-treatment) (left panel) (scale bars = 500 μm). Dotted lines indicate necrotic areas. Quantification of the necrotic area in three H&E-stained sections per mouse liver sample (right panel) (n = 4 mice per group). (m) Immunostaining for cleaved caspase-3 (cCasp3) (red) in the pericentral region of the liver, with nuclei counterstained with DAPI (blue) (scale bar = 100 μm). CV indicates the central vein. (n) Western blot analysis for cleaved caspase-3 (cCasp3) 96 h post-APAP administration (78 h post-LNP injection at indicated mRNA doses). Vinculin was used as an internal control. Statistical analysis was performed using one-way ANOVA: p < 0.01(**), p < 0.001(***), ns, not significant.

    Journal: bioRxiv

    Article Title: Enhanced liver regeneration via targeted mRNA delivery for partial in vivo reprogramming

    doi: 10.1101/2025.11.03.686120

    Figure Lengend Snippet: (a) Illustration of C12-SPM-GAL LNP-mRNA formulation. Chemical structure of the ionizable lipid C12-SPM and the lipid components with their respective molar ratios in the optimized C12-SPM-GAL LNP-mRNA formulation. (b) Biochemical assays for serum ALT and AST levels (n = 3) 24 h after intravenous (IV) administration of LNPs loaded with firefly luciferase mRNA (0.3 mg/kg) in C57BL/6 mice. PBS; PBS-injected mice, MC3; DLin-MC3-DMA LNP-injected mice, GAL; C12-SPM-GAL LNP-injected mice. (c) Time-course analysis of in vivo bioluminescence following IV administration of LNPs loaded with firefly luciferase mRNA in C57BL/6 mice (0.3 mg/kg) (n = 3 ∼ 4). (d) Detection of OSKM proteins 24 h after transfection of C12-SPM-GAL LNPs loaded with OSKM mRNA into MEFs (1 μg total OSKM mRNA for 100,000 cells, 0.25 μg for each mRNA). NT; no treatment, OSKM; OSKM mRNA-LNP treatment. (e) Experimental outline for assessing in vivo partial reprogramming by OSKM mRNA-LNP to induce hepatocyte dedifferentiation in normal wild-type mice. The PBS-injected group (PBS group) was used as a negative control, and both Luc mRNA-LNP (Luc group) and OSKM mRNA-LNP (OSKM group) were IV administered at a dose of 0.3 mg/kg. (f) Quantitative PCR analysis of liver progenitor-like cell (LPLC)-related genes in the liver 30 h post-injection (n = 4 ∼ 5). (g) Immunofluorescence staining of Sox9 and Ki-67 co-stained with Hnf4α in the liver 30 h post-injection. DAPI stains the nuclei (scale bars = 100 μm). (h) Western blot analysis for LPLC marker Sox9, cell cycle marker phosphorylated histone H3 (pHH3), and proliferating cell nuclear antigen (PCNA) in the liver 30 and 54 h post-injection. (i) Schematic illustration of C12-SPM-GAL-mediated OSKM mRNA treatment in an acetaminophen (APAP)-induced acute liver injury mouse model. C57BL/6 mice received intraperitoneal injection of APAP at a dose of 400 mg/kg after fasting for 12 h. Mice were treated with PBS (Mock group), Luc mRNA-LNP (Luc group), or OSKM mRNA-LNP (OSKM group) 18 h post-APAP administration. (j) Kaplan-Meier survival plot of mice (n = 14) in each treatment group over four days following APAP administration. Cont; normal mice, Mock; APAP injury + PBS-injected mice, Luc; APAP injury + Luc mRNA-LNP-injected mice, OSKM; APAP injury + OSKM mRNA-LNP-injected mice. (k) Blood chemistry analysis of serum AST and ALT levels 96 hours post-APAP administration (78 hours post-treatment). (l) Representative images of the whole livers and H&E staining 96 hours post-APAP administration (78 hours post-treatment) (left panel) (scale bars = 500 μm). Dotted lines indicate necrotic areas. Quantification of the necrotic area in three H&E-stained sections per mouse liver sample (right panel) (n = 4 mice per group). (m) Immunostaining for cleaved caspase-3 (cCasp3) (red) in the pericentral region of the liver, with nuclei counterstained with DAPI (blue) (scale bar = 100 μm). CV indicates the central vein. (n) Western blot analysis for cleaved caspase-3 (cCasp3) 96 h post-APAP administration (78 h post-LNP injection at indicated mRNA doses). Vinculin was used as an internal control. Statistical analysis was performed using one-way ANOVA: p < 0.01(**), p < 0.001(***), ns, not significant.

    Article Snippet: Primary mouse embryonic fibroblasts (MEFs) were isolated from ICR mouse embryos at E13.5 days (Orient Bio) as previously described .

    Techniques: Formulation, Luciferase, Injection, In Vivo, Transfection, Negative Control, Real-time Polymerase Chain Reaction, Immunofluorescence, Staining, Western Blot, Marker, Immunostaining, Control